ARK Investment Management LLC raised its holdings in shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 17.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 106,243 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,980 shares during the quarter. ARK Investment Management LLC’s holdings in Foamix Pharmaceuticals were worth $532,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Handelsbanken Fonder AB boosted its holdings in Foamix Pharmaceuticals by 7.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 390,000 shares of the specialty pharmaceutical company’s stock valued at $1,954,000 after acquiring an additional 25,500 shares during the period. Millennium Management LLC boosted its holdings in Foamix Pharmaceuticals by 2.6% during the 1st quarter. Millennium Management LLC now owns 763,296 shares of the specialty pharmaceutical company’s stock valued at $3,916,000 after acquiring an additional 19,628 shares during the period. Sofinnova Ventures Inc purchased a new position in Foamix Pharmaceuticals during the 1st quarter valued at $369,000. A.R.T. Advisors LLC purchased a new position in Foamix Pharmaceuticals during the 1st quarter valued at $104,000. Finally, Eversept Partners LLC purchased a new position in Foamix Pharmaceuticals during the 1st quarter valued at $551,000. Hedge funds and other institutional investors own 52.89% of the company’s stock.
FOMX opened at $5.97 on Wednesday. Foamix Pharmaceuticals Ltd has a 52-week low of $4.35 and a 52-week high of $7.45. The firm has a market cap of $234.88 million, a P/E ratio of -3.39 and a beta of 1.96.
A number of equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Foamix Pharmaceuticals in a report on Monday, July 16th. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th. Finally, ValuEngine upgraded Foamix Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 11th.
In other Foamix Pharmaceuticals news, CEO David Domzalski sold 8,238 shares of Foamix Pharmaceuticals stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $5.68, for a total transaction of $46,791.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 11,764 shares of company stock valued at $66,360. 3.30% of the stock is currently owned by corporate insiders.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
Recommended Story: Understanding Relative Strength Index
Want to see what other hedge funds are holding FOMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX).
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.